Each year, around 12.8 million US adults are diagnosed with back pain. Back pain represents 27.9% of all visits to physicians and is the second most frequent reason for visiting a physician and is a cause of significant work missed by U.S. workers.
The majority of participants with back pain received conservative treatment of first resort, which included advice and education with a variety of nonpharmacological therapy with or without physical therapy and/or chiropractic care. Most common types of back pain treatment included analgesics, splints, and/or muscle care. There was little difference in the proportion of participants who received all the treatments for back pain, based on their indication.
Recent findings demonstrates that [back pain](https://www.withpower.com/clinical-trials/back-pain) can be managed effectively in a short time. This includes a significant decrease of the pain and fatigue intensity.
Though the cause of back pain is not entirely clear, various factors can contribute to it, including the mechanical stress associated with normal activities required of the body's muscles and nervous system, and internal or external body positions or postures, such as standing, bending over, or sitting. Though it often seems irrational or self-defeating to be excessively cautious when performing daily activities, people who have back pain should be cautious of their physical activities and body positions, as well as other contributing causes. These include exercise, prolonged or repetitive strain on the muscles or nerves of the back, smoking, physical trauma, poor posture, diet, lack of rest, and other underlying health problems. As people ages, the back becomes stiffer and less flexible.
Back pain is the most common musculoskeletal complaint in the USA. The American Academy of Orthopaedic Surgeons (AAOS) and the American Spine Society (ASS) have published guidelines for treatment of back pain.
The [back pain](https://www.withpower.com/clinical-trials/back-pain) of chronic or acute onset was common amongst the study population and this affected daily living for the majority of individuals. More than one-half of the individuals with chronic back pain or acute back pain complained of more specific pain in the lower back. The majority of the individuals with back pain were not able to achieve work that they needed but those who were able also stated other health problems.\nThe authors conclude that the back pain of this population may represent back pain with low or moderate disease severity with pain of moderate intensity and a duration of 6 months or more. The work-related, occupational and general health issues observed in this population can be explained by the presence of chronic back pain and the pain in other body areas.
Achieving the best outcome following pico g2 4k treatment is challenging. Although there are a number of possible causes of [back pain](https://www.withpower.com/clinical-trials/back-pain), the vast majority of back pain patients respond well to pico g2 4k. By the 3-month evaluation more than 88% of patients who received pico g2 4k showed no signs of pain, only mild tenderness at the injection site. This level of success is an achievement of pico g2 4k treatment and is a reflection of its high effectiveness. Although these results can be improved by careful patient selection and close monitoring by the practitioner, pico g2 4k is a safe and effective treatment for chronic back pain.
The Pico g2 4k is feasible with a low rate of complications for spinal surgery. More and longer studies are needed to further evaluate Pico g2 4K impact on a wider cohort of patients including those at high-risk.
In recent years, many research findings and articles have been published to help treat back pain. The two groups of drugs for the treatment of chronic low back pain (CLBP) that have been described are the selective serotonin reuptake inhibitors (SSRIs) and gabapentinoids, and the combination of gabapentinoid and a SSRI; gabapentin is also administered together with SSRIs in a different combination called triple therapy. These two medications are administered as prescribed by a provider; however, they can also be self-administered, which is done under the direction of a doctor. For those patients with ongoing back pain, self-administration is the recommended method of treatment.
There was no difference in the improvement of self-reported back and neck pain between the Pico g2 4k and a placebo. Pico g2 4k is not an effective treatment for acute back pain. Pico g2 4k does not appear to offer an advantage over a placebo treatment. The study was registered on ClinicalTrials.gov. Identifier NCT00019901.
The trial results indicate that there are no significant improvements to the use of PG4k over PG4 and that there are similar rates of patients with moderate or severe pain in all groups. The only difference that did occur was that there is a trend to show the patients in the PG4k group (3.0 to 2.6 cm) were more likely to report that they had decreased their pain in response to PG4k than PG4 (2.1 to 2.0 cm). It is important to observe carefully how the pain scale data is presented. In other words, there was an increase in the pain rating (pain) for subjects who took PG 4k as opposed to those taking PG4.
The general public seems to express a preference for high quality trials, that include rigorous and well-designed methods, such as randomized controlled trials to assess the true effect of clinical interventions on outcome.